January 31, 2023

Dear Representatives Tonko, Smith and Waters:

On behalf of the Alzheimer’s Association and the Alzheimer’s Impact Movement (AIM), including our nationwide network of advocates, thank you for your continued leadership on issues and legislation important to Americans living with Alzheimer’s and other dementia, and to their caregivers. The Alzheimer’s Association and AIM write today to support the NAPA Reauthorization Act, H.R. 619, which would extend the work of the National Plan to Address Alzheimer’s Disease, among other provisions.

The burden of Alzheimer’s on individuals and families continues to grow. Today, more than 6 million Americans aged 65 and older are living with Alzheimer’s dementia and by mid-century, this number is expected to nearly double. Total payments for all individuals living with this disease are estimated at $321 billion (not including unpaid caregiving). Medicare and Medicaid are expected to cover $206 billion, or 64 percent of the total health care and long-term care payments for people with Alzheimer’s or other dementias. Total payments for health care costs, including hospice care, for people with Alzheimer’s and other dementias are projected to increase to nearly $1 trillion by 2050. These mounting costs threaten to bankrupt families, businesses, and our health care system. Unfortunately, our work is only growing more urgent.

The NAPA Reauthorization Act would continue the work of the National Plan through 2035 and would add several federal seats to the Advisory Council on Alzheimer's Research, Care and Services, including the Department of Justice, Federal Emergency Management Agency, and Social Security Administration. Language would also be added to help address health disparities among underrepresented populations, as well as healthy aging and risk reduction for Alzheimer’s disease to reflect the new sixth goal of the National Plan.

The Alzheimer’s Association and AIM deeply appreciate your continued leadership on behalf of all Americans living with Alzheimer’s and other dementia. If you have any questions about this or any other legislation, please contact Sarah Tellock, Director of Congressional Affairs, at stellock@alz-aim.org or at 202.638.8676.

Sincerely,

Rachel Conant
Vice President, Federal Affairs
Alzheimer's Association